P501 AS15
Alternative Names: P501; P501-A15Latest Information Update: 02 Oct 2021
Price :
$50 *
At a glance
- Originator GlaxoSmithKline
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Prostate cancer
Most Recent Events
- 13 Mar 2007 P501 AS15 is still in phase I/II trials for Prostate cancer in Europe
- 30 Nov 2004 Phase-I clinical trials in Prostate cancer in USA (Parenteral)
- 29 Jan 2003 Preclinical trials in Prostate cancer in USA (Parenteral)